Effects of spinal cholecystokinin receptor antagonists on morphine antinociception in a model of visceral pain in the rat.

The objective of the present study was to determine the effects of spinal cholecystokinin (CCK) receptor antagonists on morphine antinociception in a model of visceral nociception, colorectal distension, in rats with chronic colonic inflammation and vehicle-treated controls. Three to five days after intracolonic instillation of 2,4,6-trinitrobenzenesulfonic acid (TNBS), an enhanced visceromotor response to all pressures of colorectal distension (10-80 mm Hg) was evident. The ED(50) of intrathecal morphine (0.93 microgram) in vehicle-treated rats produced significantly greater antinociception in TNBS-treated rats. Intrathecal proglumide, a nonselective CCK receptor antagonist, dose dependently enhanced the antinociceptive effect of morphine in vehicle-treated rats, but not in TNBS-treated rats. Similarly, L-365, 260, a specific CCK(B) receptor antagonist, dose dependently increased morphine's antinociceptive effects in vehicle-treated rats but had no effect in rats with TNBS-induced colonic inflammation. L-364,718, a specific CCK(A) receptor antagonist, had no effect on morphine antinociception in either vehicle-treated or TNBS-treated rats. These data indicate that CCK, acting at the CCK(B) receptor, is involved in modulating morphine antinociception following a noxious visceral stimulus. However, CCK receptor antagonists no longer enhance morphine antinociception after instillation of intracolonic TNBS, suggesting that visceral inflammation may lead to a reduction in spinal CCK release.

[1]  G. Gebhart,et al.  Effects of kappa opioids in the inflamed rat colon , 1999, PAIN.

[2]  P. Cabot,et al.  Opioids in Pain Control: Peripheral Opioid Analgesia: Mechanisms and Clinical Implications , 1998 .

[3]  G. Gebhart,et al.  Effects of kappa-opioid receptor agonists on responses to colorectal distension in rats with and without acute colonic inflammation. , 1998, The Journal of pharmacology and experimental therapeutics.

[4]  E. Kalso,et al.  Neuropeptide FF in the Rat Spinal Cord During Carrageenan Inflammation , 1997, Peptides.

[5]  A I Basbaum,et al.  Cholecystokinin and enkephalin in brain stem pain modulating circuits , 1997, Neuroreport.

[6]  G. Guilbaud,et al.  Prevention of tolerance to the antinociceptive effects of systemic morphine by a selective cholecystokinin-B receptor antagonist in a rat model of peripheral neuropathy. , 1997, The Journal of pharmacology and experimental therapeutics.

[7]  L Bueno,et al.  Mediators and pharmacology of visceral sensitivity: from basic to clinical investigations. , 1997, Gastroenterology.

[8]  G. Woodruff,et al.  Effect of CCK receptor antagonists on the antinociceptive, reinforcing and gut motility properties of morphine , 1996, British journal of pharmacology.

[9]  H. Yamamura,et al.  Enhancement of morphine antinociception by a CCKB antagonist in mice is mediated via opioid delta receptors. , 1996, Journal of Pharmacology and Experimental Therapeutics.

[10]  M. Neurath,et al.  Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin‐10 or antibodies to interleukin‐12 , 1996, European journal of immunology.

[11]  G. Gebhart.  Visceral nociception: consequences, modulation and the future. , 1995, European journal of anaesthesiology. Supplement.

[12]  H. Loh,et al.  Ca2+ channel and adenylyl cyclase modulation by cloned mu-opioid receptors in GH3 cells. , 1995, Molecular Pharmacology.

[13]  F. Porreca,et al.  The increase in morphine antinociceptive potency produced by carrageenan-induced hindpaw inflammation is blocked by naltrindole, a selective δ-opioid antagonist , 1995, Neuroscience Letters.

[14]  H. Yamamura,et al.  Antisense oligodeoxynucleotide to the CCKB receptor produces naltrindole- and [Leu5]enkephalin antiserum-sensitive enhancement of morphine antinociception. , 1994, Neuroreport.

[15]  T. Vanderah,et al.  Naltrindole, an opioid δ antagonist, blocks the enhancement of morphine-antinociception induced by a CCKB antagonist in the rat , 1994, Neuroscience Letters.

[16]  G. Gebhart,et al.  Mechanosensitive properties of pelvic nerve afferent fibers innervating the urinary bladder of the rat. , 1994, Journal of neurophysiology.

[17]  R. Schmidt,et al.  Sensitization of insensitive branches of C nociceptors in human skin. , 1994, The Journal of physiology.

[18]  M. Fournié-Zaluski,et al.  Cholecystokinin B antagonists strongly potentiate antinociception mediated by endogenous enkephalins. , 1994, The Journal of pharmacology and experimental therapeutics.

[19]  Xiao-jun Xu,et al.  Cholecystokinin and morphine analgesia: variations on a theme. , 1994, Trends in pharmacological sciences.

[20]  J. Han,et al.  Increased release of immunoreactive cholecystokinin octapeptide by morphine and potentiation of mu-opioid analgesia by CCKB receptor antagonist L-365,260 in rat spinal cord. , 1993, European journal of pharmacology.

[21]  A. Dickenson,et al.  Cholecystokinin as a factor in the enhanced potency of spinal morphine following carrageenin inflammation , 1993, British journal of pharmacology.

[22]  A. Dickenson,et al.  Alterations in neuronal excitability and the potency of spinal mu, delta and kappa opioids after carrageenan-induced inflammation , 1992, PAIN.

[23]  Jisheng Han,et al.  Mobilization of calcium from intracellular stores as one of the mechanisms underlying the antiopioid effect of cholecystokinin octapeptide , 1992, Peptides.

[24]  R. Jensen,et al.  Purification, molecular cloning, and functional expression of the cholecystokinin receptor from rat pancreas. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[25]  D. Price,et al.  Cholecystokinin and its antagonist lorglumide respectively attenuate and facilitate morphine-induced inhibition of C-fiber evoked discharges of dorsal horn nociceptive neurons , 1991, Brain Research.

[26]  B. Costall,et al.  Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[27]  S. Iversen,et al.  Morphine-induced analgesia in the rat paw pressure test is blocked by CCK and enhanced by the CCK antagonist MK-329 , 1989, Neuropharmacology.

[28]  J. Wallace,et al.  Hapten-induced model of chronic inflammation and ulceration in the rat colon. , 1989, Gastroenterology.

[29]  T. Ness,et al.  Colorectal distension as a noxious visceral stimulus: physiologic and pharmacologic characterization of pseudaffective reflexes in the rat , 1988, Brain Research.

[30]  H. Handwerker,et al.  The effect of carrageenan-induced inflammation on the sensitivity of unmyelinated skin nociceptors in the rat , 1987, Pain.

[31]  J. Lauterborn,et al.  Co-localization of enkephalin and cholecystokinin in discrete areas of rat brain , 1987, Brain Research.

[32]  A. Herz,et al.  A model of chronic pain in the rat: functional correlates of alterations in the activity of opioid systems , 1987, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[33]  Paul R. McHugh,et al.  Two brain cholecystokinin receptors: implications for behavioral actions , 1986, Brain Research.

[34]  K. Mullane,et al.  Myeloperoxidase activity as a quantitative assessment of neutrophil infiltration into ischemic myocardium. , 1985, Journal of pharmacological methods.

[35]  L. Watkins,et al.  Potentiation of morphine analgesia by the cholecystokinin antagonist proglumide , 1985, Brain Research.

[36]  L. Watkins,et al.  Cholecystokinin antagonists selectively potentiate analgesia induced by endogenous opiates , 1985, Brain Research.

[37]  W. Stenson,et al.  Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity: Assessment of inflammation in rat and hamster models , 1984 .

[38]  L. Watkins,et al.  Potentiation of opiate analgesia and apparent reversal of morphine tolerance by proglumide. , 1984, Science.

[39]  W. Stenson,et al.  Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. , 1984, Gastroenterology.

[40]  L. Watkins,et al.  Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia. , 1983, Science.

[41]  R. Barrett,et al.  The effects of receptor selective opioid peptides on morphine-induced analgesia. , 1982, European journal of pharmacology.